Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management

Pier Luigi Dodi Department of Veterinary Medicine Sciences, University of Parma, Parma, Italy Abstract: Keratoconjunctivitis sicca (KCS) is a frequent canine ophthalmic disease, resulting from the deficiency of one or more elements in the precorneal tear film. There are different known causes of KC...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autor principal:	Dodi PL
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2015
Materias:	Veterinary medicine SF600-1100
Acceso en línea:	https://doaj.org/article/4897bed0492747609d72397c876eaa32
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:4897bed0492747609d72397c876eaa32
record_format	dspace
spelling	oai:doaj.org-article:4897bed0492747609d72397c876eaa322021-12-02T00:17:27ZImmune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management2230-2034https://doaj.org/article/4897bed0492747609d72397c876eaa322015-10-01T00:00:00Zhttps://www.dovepress.com/immune-mediated-keratoconjunctivitis-sicca-in-dogs-current-perspective-peer-reviewed-article-VMRRhttps://doaj.org/toc/2230-2034Pier Luigi Dodi Department of Veterinary Medicine Sciences, University of Parma, Parma, Italy Abstract: Keratoconjunctivitis sicca (KCS) is a frequent canine ophthalmic disease, resulting from the deficiency of one or more elements in the precorneal tear film. There are different known causes of KCS in dogs, including congenital, metabolic, infectious, drug induced, neurogenic, radiation, iatrogenic, idiopathic, and immune mediated, though the last one is the most prevalent form in dogs. Initially, clinical signs of KCS include blepharospasm caused by ocular pain, mucoid to mucopurulent ocular discharge, and conjunctival hyperemia; secondary bacterial infection may also occur, with chronicity, corneal epithelial hyperplasia, pigmentation, neovascularization, and corneal ulceration. The diagnosis of KCS is based on the presence of consistent clinical signs and measurement of decreased aqueous tear production using the Schirmer tear test. Therapy is based on administering the following topical drugs: ocular lubricant, mucolytics, antibiotics, corticosteroids, pilocarpine, and immunomodulators. These last drugs (eg, cyclosporine, pimecrolimus, and tacrolimus) have immunosuppressive activity and stimulate tear production. Furthermore, the nerve growth factor is a new subject matter of the research. Although these therapies are advantageous, stimulation of natural tear production seems to provide the highest recovery in clinical signs and prevention of vision loss. The goal of the following article is to describe the recent developments about KCS in dogs emphasizing the use of new therapies. Keywords: dogs, keratoconjunctivitis sicca, treatment, NGFDodi PLDove Medical PressarticleVeterinary medicineSF600-1100ENVeterinary Medicine: Research and Reports, Vol 2015, Iss default, Pp 341-347 (2015)
institution	DOAJ
collection	DOAJ
language	EN
topic	Veterinary medicine SF600-1100
spellingShingle	Veterinary medicine SF600-1100 Dodi PL Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
description	Pier Luigi Dodi Department of Veterinary Medicine Sciences, University of Parma, Parma, Italy Abstract: Keratoconjunctivitis sicca (KCS) is a frequent canine ophthalmic disease, resulting from the deficiency of one or more elements in the precorneal tear film. There are different known causes of KCS in dogs, including congenital, metabolic, infectious, drug induced, neurogenic, radiation, iatrogenic, idiopathic, and immune mediated, though the last one is the most prevalent form in dogs. Initially, clinical signs of KCS include blepharospasm caused by ocular pain, mucoid to mucopurulent ocular discharge, and conjunctival hyperemia; secondary bacterial infection may also occur, with chronicity, corneal epithelial hyperplasia, pigmentation, neovascularization, and corneal ulceration. The diagnosis of KCS is based on the presence of consistent clinical signs and measurement of decreased aqueous tear production using the Schirmer tear test. Therapy is based on administering the following topical drugs: ocular lubricant, mucolytics, antibiotics, corticosteroids, pilocarpine, and immunomodulators. These last drugs (eg, cyclosporine, pimecrolimus, and tacrolimus) have immunosuppressive activity and stimulate tear production. Furthermore, the nerve growth factor is a new subject matter of the research. Although these therapies are advantageous, stimulation of natural tear production seems to provide the highest recovery in clinical signs and prevention of vision loss. The goal of the following article is to describe the recent developments about KCS in dogs emphasizing the use of new therapies. Keywords: dogs, keratoconjunctivitis sicca, treatment, NGF
format	article
author	Dodi PL
author_facet	Dodi PL
author_sort	Dodi PL
title	Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
title_short	Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
title_full	Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
title_fullStr	Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
title_full_unstemmed	Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
title_sort	immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management
publisher	Dove Medical Press
publishDate	2015
url	https://doaj.org/article/4897bed0492747609d72397c876eaa32
work_keys_str_mv	AT dodipl immunemediatedkeratoconjunctivitissiccaindogscurrentperspectivesonmanagement
_version_	1718403796987543552

Immune-mediated keratoconjunctivitis sicca in dogs: current perspectives on management

Ejemplares similares